Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
0.6706
-0.0150 (-2.19%)
At close: Aug 1, 2025, 4:00 PM
0.7030
+0.0324 (4.83%)
After-hours: Aug 1, 2025, 7:43 PM EDT
Altus Power Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
152
Market Cap
55.47M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 24.99M | 15.26M | 156.83% |
Dec 31, 2021 | 9.73M | -8.17M | -45.65% |
Dec 31, 2020 | 17.90M | 16.91M | 1,699.30% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ACET News
- 9 days ago - Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Business Wire
- 2 months ago - Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference - Business Wire
- 3 months ago - Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 3 months ago - Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference - Business Wire
- 3 months ago - Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Business Wire
- 3 months ago - Adicet Bio Appoints Michael Grissinger to the Board of Directors - Business Wire
- 4 months ago - Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire